Cytek Biosciences

CTKB

Market cap $597M

FREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the opening of a new innovation center in Bellevue, Washington, marking the relocation of its previous Seattle-area operations to a dedicated facility designed to support research and development (R&D) while strengthening collaboration and customer engagement.

FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that the company will be participating in the upcoming Singular Research's Las Vegas Invitational Conference taking place June 14-16, 2026.

At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer.

Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.09 per share a year ago.

FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026.

FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026.

Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek's manufacturing capacity and regional service.

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.07 per share a year ago.

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript